Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 156 of 156 entries
Sorted by: Best Match Show Resources per page
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

European urology

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.
PMID: 28705540
Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11.

BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.OBJECTIVE: To report...

Cite
Parker CC, Coleman RE, Sartor O, et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2017;73(3):427-435doi: 10.1016/j.eururo.2017.06.021.
Parker, C. C., Coleman, R. E., Sartor, O., Vogelzang, N. J., Bottomley, D., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Bruland, �. �. S., Petrenciuc, O., Staudacher, K., Li, R., & Nilsson, S. (2018). Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European urology, 73(3), 427-435. https://doi.org/10.1016/j.eururo.2017.06.021
Parker, Christopher C, et al. "Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial." European urology vol. 73,3 (2018): 427-435. doi: https://doi.org/10.1016/j.eururo.2017.06.021
Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11. PMID: 28705540.
Copy Download .nbib Format: NLM
The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy.

Neuro-oncology practice

Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D.
PMID: 31386073
Neurooncol Pract. 2019 Jul;6(4):274-282. doi: 10.1093/nop/npy038. Epub 2018 Dec 03.

BACKGROUND: This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT).METHODS: Adult patients with brain metastases received WBRT and were randomized to receive...

Cite
Laack NN, Pugh SL, Brown PD, et al. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract. 2018;6(4):274-282doi: 10.1093/nop/npy038.
Laack, N. N., Pugh, S. L., Brown, P. D., Fox, S., Wefel, J. S., Meyers, C., Choucair, A., Khuntia, D., Suh, J. H., Roberge, D., Wendland, M. M., & Bruner, D. (2019). The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neuro-oncology practice, 6(4), 274-282. https://doi.org/10.1093/nop/npy038
Laack, Nadia N, et al. "The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy." Neuro-oncology practice vol. 6,4 (2019): 274-282. doi: https://doi.org/10.1093/nop/npy038
Laack NN, Pugh SL, Brown PD, Fox S, Wefel JS, Meyers C, Choucair A, Khuntia D, Suh JH, Roberge D, Wendland MM, Bruner D. The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neurooncol Pract. 2019 Jul;6(4):274-282. doi: 10.1093/nop/npy038. Epub 2018 Dec 03. PMID: 31386073; PMCID: PMC6660822.
Copy Download .nbib Format: NLM
Phosphate Treatment of Lead-Contaminated Soil: Effects on Water Quality, Plant Uptake, and Lead Speciation.

Journal of environmental quality

Weber JS, Goyne KW, Luxton TP, Thompson AL.
PMID: 26437094
J Environ Qual. 2015 Jul;44(4):1127-36. doi: 10.2134/jeq2014.10.0447.

Water quality threats associated with using phosphate-based amendments to remediate Pb-contaminated soils are a concern, particularly in riparian areas. This study investigated the effects of P application rates to a Pb-contaminated alluvial soil on Pb and P loss via...

Cite
Weber JS, Goyne KW, Luxton TP, et al. Phosphate Treatment of Lead-Contaminated Soil: Effects on Water Quality, Plant Uptake, and Lead Speciation. J Environ Qual. 2015;44(4):1127-36doi: 10.2134/jeq2014.10.0447.
Weber, J. S., Goyne, K. W., Luxton, T. P., & Thompson, A. L. (2015). Phosphate Treatment of Lead-Contaminated Soil: Effects on Water Quality, Plant Uptake, and Lead Speciation. Journal of environmental quality, 44(4), 1127-36. https://doi.org/10.2134/jeq2014.10.0447
Weber, John S, et al. "Phosphate Treatment of Lead-Contaminated Soil: Effects on Water Quality, Plant Uptake, and Lead Speciation." Journal of environmental quality vol. 44,4 (2015): 1127-36. doi: https://doi.org/10.2134/jeq2014.10.0447
Weber JS, Goyne KW, Luxton TP, Thompson AL. Phosphate Treatment of Lead-Contaminated Soil: Effects on Water Quality, Plant Uptake, and Lead Speciation. J Environ Qual. 2015 Jul;44(4):1127-36. doi: 10.2134/jeq2014.10.0447. PMID: 26437094.
Copy Download .nbib Format: NLM
Reply to F. Liang et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Weber JS, Jiang J.
PMID: 28591545
J Clin Oncol. 2017 Jun 10;35(17):1968. doi: 10.1200/JCO.2017.72.2645. Epub 2017 Mar 06.

No abstract available.

Cite
Weber JS, Jiang J. Reply to F. Liang et al. J Clin Oncol. 2017;35(17):1968doi: 10.1200/JCO.2017.72.2645.
Weber, J. S., & Jiang, J. (2017). Reply to F. Liang et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(17), 1968. https://doi.org/10.1200/JCO.2017.72.2645
Weber, Jeffrey S, and Jiang, Joel. "Reply to F. Liang et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 35,17 (2017): 1968. doi: https://doi.org/10.1200/JCO.2017.72.2645
Weber JS, Jiang J. Reply to F. Liang et al. J Clin Oncol. 2017 Jun 10;35(17):1968. doi: 10.1200/JCO.2017.72.2645. Epub 2017 Mar 06. PMID: 28591545.
Copy Download .nbib Format: NLM
Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients.

Journal of neuro-oncology

Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y.
PMID: 34817796
J Neurooncol. 2022 Jan;156(1):185-193. doi: 10.1007/s11060-021-03905-5. Epub 2021 Nov 24.

PURPOSE: Impaired neurocognitive function (NCF) is extremely common in patients with higher grade primary brain tumor. We previously reported evidence of genetic variants associated with NCF in glioma patients prior to treatment. However, little is known about the effect...

Cite
Wefel JS, Zhou R, Sulman EP, et al. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. J Neurooncol. 2021;156(1):185-193doi: 10.1007/s11060-021-03905-5.
Wefel, J. S., Zhou, R., Sulman, E. P., Boehling, N. S., Armstrong, G. N., Tsavachidis, S., Liang, F. W., Etzel, C. J., Kahalley, L. S., Small, B. J., Scheurer, M. E., Bondy, M. L., & Liu, Y. (2022). Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. Journal of neuro-oncology, 156(1), 185-193. https://doi.org/10.1007/s11060-021-03905-5
Wefel, Jeffrey S, et al. "Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients." Journal of neuro-oncology vol. 156,1 (2022): 185-193. doi: https://doi.org/10.1007/s11060-021-03905-5
Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. J Neurooncol. 2022 Jan;156(1):185-193. doi: 10.1007/s11060-021-03905-5. Epub 2021 Nov 24. PMID: 34817796.
Copy Download .nbib Format: NLM
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M.
PMID: 34724386
J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 01.

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy.METHODS: A multidisciplinary panel of medical oncology, neurology, hematology, emergency medicine, nursing,...

Cite
Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978-3992doi: 10.1200/JCO.21.01992.
Santomasso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Funchain, P., Jaiyesimi, I., Mammen, J. S., Naidoo, J., Naing, A., Phillips, T., Porter, L. D., Reichner, C. A., Seigel, C., Song, J. M., Spira, A., Suarez-Almazor, M., Swami, U., Thompson, J. A., Vikas, P., Wang, Y., Weber, J. S., Bollin, K., & Ghosh, M. (2021). Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(35), 3978-3992. https://doi.org/10.1200/JCO.21.01992
Santomasso, Bianca D, et al. "Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,35 (2021): 3978-3992. doi: https://doi.org/10.1200/JCO.21.01992
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 01. PMID: 34724386.
Copy Download .nbib Format: NLM
Changes in Segmental and Lumbar Lordosis After Lateral Lumbar Interbody Fusion With Different Lordotic Cage Angulations.

International journal of spine surgery

Bakare AA, Fessler DR, Wewel JT, Fontes RBV, Fessler RG, O'Toole JE.
PMID: 33963028
Int J Spine Surg. 2021 Jun;15(3):440-448. doi: 10.14444/8066. Epub 2021 May 07.

BACKGROUND: Lateral lumbar interbody fusion (LLIF) affords a wide operative corridor to allow for a large interbody cage implantation for segmental reconstruction. There is a paucity of data describing segmental lordosis (SL) achieved with lordotic implants of varying angles....

Cite
Bakare AA, Fessler DR, Wewel JT, et al. Changes in Segmental and Lumbar Lordosis After Lateral Lumbar Interbody Fusion With Different Lordotic Cage Angulations. Int J Spine Surg. 2021;15(3):440-448doi: 10.14444/8066.
Bakare, A. A., Fessler, D. R., Wewel, J. T., Fontes, R. B. V., Fessler, R. G., & O'Toole, J. E. (2021). Changes in Segmental and Lumbar Lordosis After Lateral Lumbar Interbody Fusion With Different Lordotic Cage Angulations. International journal of spine surgery, 15(3), 440-448. https://doi.org/10.14444/8066
Bakare, Adewale A, et al. "Changes in Segmental and Lumbar Lordosis After Lateral Lumbar Interbody Fusion With Different Lordotic Cage Angulations." International journal of spine surgery vol. 15,3 (2021): 440-448. doi: https://doi.org/10.14444/8066
Bakare AA, Fessler DR, Wewel JT, Fontes RBV, Fessler RG, O'Toole JE. Changes in Segmental and Lumbar Lordosis After Lateral Lumbar Interbody Fusion With Different Lordotic Cage Angulations. Int J Spine Surg. 2021 Jun;15(3):440-448. doi: 10.14444/8066. Epub 2021 May 07. PMID: 33963028; PMCID: PMC8176834.
Copy Download .nbib Format: NLM
Preservation of neurocognitive function in the treatment of brain metastases.

Neuro-oncology advances

Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS.
PMID: 34859237
Neurooncol Adv. 2021 Nov 27;3:v96-v107. doi: 10.1093/noajnl/vdab122. eCollection 2021 Nov.

Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the metastasis, including surgery, radiation therapy, chemotherapy, and immunotherapy. In...

Cite
Parsons MW, Peters KB, Floyd SR, et al. Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv. 2021;3:v96-v107doi: 10.1093/noajnl/vdab122.
Parsons, M. W., Peters, K. B., Floyd, S. R., Brown, P., & Wefel, J. S. (2021). Preservation of neurocognitive function in the treatment of brain metastases. Neuro-oncology advances, 3v96-v107. https://doi.org/10.1093/noajnl/vdab122
Parsons, Michael W, et al. "Preservation of neurocognitive function in the treatment of brain metastases." Neuro-oncology advances vol. 3 (2021): v96-v107. doi: https://doi.org/10.1093/noajnl/vdab122
Parsons MW, Peters KB, Floyd SR, Brown P, Wefel JS. Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv. 2021 Nov 27;3:v96-v107. doi: 10.1093/noajnl/vdab122. eCollection 2021 Nov. PMID: 34859237; PMCID: PMC8633744.
Copy Download .nbib Format: NLM
Measurement of the Iron Spectrum in Cosmic Rays from 10  GeV/n to 2.0  TeV/n with the Calorimetric Electron Telescope on the International Space Station.

Physical review letters

Adriani O, Akaike Y, Asano K, Asaoka Y, Berti E, Bigongiari G, Binns WR, Bongi M, Brogi P, Bruno A, Buckley JH, Cannady N, Castellini G, Checchia C, Cherry ML, Collazuol G, Ebisawa K, Fuke H, Gonzi S, Guzik TG, Hams T, Hibino K, Ichimura M, Ioka K, Ishizaki W, Israel MH, Kasahara K, Kataoka J, Kataoka R, Katayose Y, Kato C, Kawanaka N, Kawakubo Y, Kobayashi K, Kohri K, Krawczynski HS, Krizmanic JF, Link J, Maestro P, Marrocchesi PS, Messineo AM, Mitchell JW, Miyake S, Moiseev AA, Mori M, Mori N, Motz HM, Munakata K, Nakahira S, Nishimura J, de Nolfo GA, Okuno S, Ormes JF, Ospina N, Ozawa S, Pacini L, Papini P, Rauch BF, Ricciarini SB, Sakai K, Sakamoto T, Sasaki M, Shimizu Y, Shiomi A, Spillantini P, Stolzi F, Sugita S, Sulaj A, Takita M, Tamura T, Terasawa T, Torii S, Tsunesada Y, Uchihori Y, Vannuccini E, Wefel JP, Yamaoka K, Yanagita S, Yoshida A, Yoshida K.
PMID: 34213922
Phys Rev Lett. 2021 Jun 18;126(24):241101. doi: 10.1103/PhysRevLett.126.241101.

The Calorimetric Electron Telescope (CALET), in operation on the International Space Station since 2015, collected a large sample of cosmic-ray iron over a wide energy interval. In this Letter a measurement of the iron spectrum is presented in the...

Cite
Adriani O, Akaike Y, Asano K, et al. Measurement of the Iron Spectrum in Cosmic Rays from 10  GeV/n to 2.0  TeV/n with the Calorimetric Electron Telescope on the International Space Station. Phys Rev Lett. 2021;126(24):241101doi: 10.1103/PhysRevLett.126.241101.
Adriani, O., Akaike, Y., Asano, K., Asaoka, Y., Berti, E., Bigongiari, G., Binns, W. R., Bongi, M., Brogi, P., Bruno, A., Buckley, J. H., Cannady, N., Castellini, G., Checchia, C., Cherry, M. L., Collazuol, G., Ebisawa, K., Fuke, H., Gonzi, S., Guzik, T. G., Hams, T., Hibino, K., Ichimura, M., Ioka, K., Ishizaki, W., Israel, M. H., Kasahara, K., Kataoka, J., Kataoka, R., Katayose, Y., Kato, C., Kawanaka, N., Kawakubo, Y., Kobayashi, K., Kohri, K., Krawczynski, H. S., Krizmanic, J. F., Link, J., Maestro, P., Marrocchesi, P. S., Messineo, A. M., Mitchell, J. W., Miyake, S., Moiseev, A. A., Mori, M., Mori, N., Motz, H. M., Munakata, K., Nakahira, S., Nishimura, J., de Nolfo, G. A., Okuno, S., Ormes, J. F., Ospina, N., Ozawa, S., Pacini, L., Papini, P., Rauch, B. F., Ricciarini, S. B., Sakai, K., Sakamoto, T., Sasaki, M., Shimizu, Y., Shiomi, A., Spillantini, P., Stolzi, F., Sugita, S., Sulaj, A., Takita, M., Tamura, T., Terasawa, T., Torii, S., Tsunesada, Y., Uchihori, Y., Vannuccini, E., Wefel, J. P., Yamaoka, K., Yanagita, S., Yoshida, A., Yoshida, K. (2021). Measurement of the Iron Spectrum in Cosmic Rays from 10  GeV/n to 2.0  TeV/n with the Calorimetric Electron Telescope on the International Space Station. Physical review letters, 126(24), 241101. https://doi.org/10.1103/PhysRevLett.126.241101
Adriani, O, et al. "Measurement of the Iron Spectrum in Cosmic Rays from 10  GeV/n to 2.0  TeV/n with the Calorimetric Electron Telescope on the International Space Station." Physical review letters vol. 126,24 (2021): 241101. doi: https://doi.org/10.1103/PhysRevLett.126.241101
Adriani O, Akaike Y, Asano K, Asaoka Y, Berti E, Bigongiari G, Binns WR, Bongi M, Brogi P, Bruno A, Buckley JH, Cannady N, Castellini G, Checchia C, Cherry ML, Collazuol G, Ebisawa K, Fuke H, Gonzi S, Guzik TG, Hams T, Hibino K, Ichimura M, Ioka K, Ishizaki W, Israel MH, Kasahara K, Kataoka J, Kataoka R, Katayose Y, Kato C, Kawanaka N, Kawakubo Y, Kobayashi K, Kohri K, Krawczynski HS, Krizmanic JF, Link J, Maestro P, Marrocchesi PS, Messineo AM, Mitchell JW, Miyake S, Moiseev AA, Mori M, Mori N, Motz HM, Munakata K, Nakahira S, Nishimura J, de Nolfo GA, Okuno S, Ormes JF, Ospina N, Ozawa S, Pacini L, Papini P, Rauch BF, Ricciarini SB, Sakai K, Sakamoto T, Sasaki M, Shimizu Y, Shiomi A, Spillantini P, Stolzi F, Sugita S, Sulaj A, Takita M, Tamura T, Terasawa T, Torii S, Tsunesada Y, Uchihori Y, Vannuccini E, Wefel JP, Yamaoka K, Yanagita S, Yoshida A, Yoshida K. Measurement of the Iron Spectrum in Cosmic Rays from 10  GeV/n to 2.0  TeV/n with the Calorimetric Electron Telescope on the International Space Station. Phys Rev Lett. 2021 Jun 18;126(24):241101. doi: 10.1103/PhysRevLett.126.241101. PMID: 34213922.
Copy Download .nbib Format: NLM
Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Agur T, Wedel J, Bose S, Sahankumari AGP, Goodman D, Kong SW, Ghosh CC, Briscoe DM.
PMID: 34687147
Am J Transplant. 2021 Oct 22; doi: 10.1111/ajt.16872. Epub 2021 Oct 22.

The statin family of therapeutics is widely used clinically as cholesterol lowering agents, and their effects to target intracellular mevalonate production is a key mechanism of action. In this study, we performed full transcriptomic RNA sequencing and qPCR to...

Cite
Agur T, Wedel J, Bose S, et al. Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4. Am J Transplant. 2021;doi: 10.1111/ajt.16872.
Agur, T., Wedel, J., Bose, S., Sahankumari, A. G. P., Goodman, D., Kong, S. W., Ghosh, C. C., & Briscoe, D. M. (2021). Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, . https://doi.org/10.1111/ajt.16872
Agur, Timna, et al. "Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. (2021). doi: https://doi.org/10.1111/ajt.16872
Agur T, Wedel J, Bose S, Sahankumari AGP, Goodman D, Kong SW, Ghosh CC, Briscoe DM. Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4. Am J Transplant. 2021 Oct 22; doi: 10.1111/ajt.16872. Epub 2021 Oct 22. PMID: 34687147.
Copy Download .nbib Format: NLM
Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study.

JMIR formative research

Würstle S, Erber J, Hanselmann M, Hoffmann D, Werfel S, Hering S, Weidlich S, Schneider J, Franke R, Maier M, Henkel A, Schmid RM, Protzer U, Laxy M, Spinner CD.
PMID: 34803022
JMIR Form Res. 2021 Nov 21; doi: 10.2196/32564. Epub 2021 Nov 21.

BACKGROUND: Large-scale PCR-based SARS-CoV-2 testing is expensive, resource-intensive, and time-consuming. A self-collection approach is a probable alternative; however, it requires evaluating the feasibility, expenses, and the ability to prevent infections.OBJECTIVE: This study aims to compare an innovative self-collection approach...

Cite
Würstle S, Erber J, Hanselmann M, et al. Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study. JMIR Form Res. 2021;doi: 10.2196/32564.
Würstle, S., Erber, J., Hanselmann, M., Hoffmann, D., Werfel, S., Hering, S., Weidlich, S., Schneider, J., Franke, R., Maier, M., Henkel, A., Schmid, R. M., Protzer, U., Laxy, M., & Spinner, C. D. (2021). Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study. JMIR formative research, . https://doi.org/10.2196/32564
Würstle, Silvia, et al. "Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study." JMIR formative research vol. (2021). doi: https://doi.org/10.2196/32564
Würstle S, Erber J, Hanselmann M, Hoffmann D, Werfel S, Hering S, Weidlich S, Schneider J, Franke R, Maier M, Henkel A, Schmid RM, Protzer U, Laxy M, Spinner CD. Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study. JMIR Form Res. 2021 Nov 21; doi: 10.2196/32564. Epub 2021 Nov 21. PMID: 34803022.
Copy Download .nbib Format: NLM
Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.

The oncologist

Petrillo LA, Zhou AZ, Sullivan R, Volandes A, Greer JA, Temel JS, El-Jawahri A, Allen PJ, Sonnert G.
PMID: 34409698
Oncologist. 2021 Nov;26(11):e2090-e2093. doi: 10.1002/onco.13945. Epub 2021 Aug 28.

BACKGROUND: Immunotherapy is the first-line treatment for melanoma and lung cancer and brings new risks of immune-related adverse events. We aimed to describe patients' knowledge about risks, benefits, and goals of immunotherapy.MATERIALS AND METHODS: We conducted a cross-sectional study...

Cite
Petrillo LA, Zhou AZ, Sullivan R, et al. Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. Oncologist. 2021;26(11):e2090-e2093doi: 10.1002/onco.13945.
Petrillo, L. A., Zhou, A. Z., Sullivan, R., Volandes, A., Greer, J. A., Temel, J. S., El-Jawahri, A., Allen, P. J., & Sonnert, G. (2021). Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. The oncologist, 26(11), e2090-e2093. https://doi.org/10.1002/onco.13945
Petrillo, Laura A, et al. "Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer." The oncologist vol. 26,11 (2021): e2090-e2093. doi: https://doi.org/10.1002/onco.13945
Petrillo LA, Zhou AZ, Sullivan R, Volandes A, Greer JA, Temel JS, El-Jawahri A, Allen PJ, Sonnert G. Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. Oncologist. 2021 Nov;26(11):e2090-e2093. doi: 10.1002/onco.13945. Epub 2021 Aug 28. PMID: 34409698; PMCID: PMC8571764.
Copy Download .nbib Format: NLM
Showing 145 to 156 of 156 entries